Orelabrutinib |
| Catalog No.GC39634 |
오레브루티닙(ICP-022)은 잠재적인 항종양 활성이 있는 강력하고 경구 활성이며 비가역적인 브루톤 티로신 키나제(BTK) 억제제입니다. 오레브루티닙은 B-세포 항원 수용체(BCR) 신호 전달 경로의 활성화와 다운스트림 생존 경로의 BTK 매개 활성화를 모두 방지하여 BTK를 과발현하는 악성 B-세포의 성장을 억제합니다.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1655504-04-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Orelabrutinib (ICP-022) is a potent, orally active, and irreversible Bruton's tyrosine kinase (BTK) inhibitor. Orelabrutinib has the potential for B-cell malignancies treatment[1].
[1]. Wei Xu, et al. Safety, Tolerability and Efficacy of Orelabrutinib, Once a Day, to Treat Chinese Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Cell Leukemia. Blood (2019) 134 (Supplement_1): 4319.
Average Rating: 5 (Based on Reviews and 34 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *